Open an account

Illumina

ILMN · NASDAQ

$267.93+$5.27 (+2.01%)TodayMarket closed ·
Prev close $262.66

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,600 full-time employees. The company went IPO on 2000-06-28. The firm's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. The company also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.

Employees
8,600
Headquarters
San Diego, California
Listed
Jun 28, 2000
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
illumina.com

ILMN key statistics

Market cap
39.66B
Price-earnings ratio
49.00
Dividend yield
—
Average volume
2.81M
Volume
1.04M
Open price
$264.13
High today
$271.43
Low today
$260.15
52 Week high
$309.35
52 Week low
$93.50

Illumina (ILMN) at a glance

As of Oct 20, 2026, Illumina (ILMN) shares are priced at $267.93, giving the company a market cap of 39.66B and a price-to-earnings ratio of 49.00.

Today the stock has traded between $260.15 and $271.43. The current price is 3.0% above the day's low and 1.3% below its high.

Volume so far is 1.04M shares, below the average of 2.81M shares a day.

Over the past year Illumina has ranged from $93.50 to $309.35, and now sits 81% of the way up that range.

Illumina met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $1.31 per share against an estimate of $1.25.

The average analyst price target is $209.59, 21.8% below the current price, from 17 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

53%of 17 analyst ratings say Buy
  • Buy52.9%
  • Hold29.4%
  • Sell17.6%
Price target · 23 analystsAvg $209.59
Low
$114.13
Now
$267.93
High
$320.25

ILMN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 10.7% on average.

  1. Q3 FY24: reported $1.14 per share against an estimate of $0.8985
  2. Q4 FY24: reported $0.86 per share against an estimate of $0.9324
  3. Q1 FY25: reported $0.97 per share against an estimate of $0.9573
  4. Q2 FY25: reported $1.19 per share against an estimate of $1.03
  5. Q3 FY25: reported $1.34 per share against an estimate of $1.19
  6. Q4 FY25: reported $1.15 per share against an estimate of $1.08
  7. Q1 FY26: reported $1.15 per share against an estimate of $1.08
  8. Q2 FY26: reported $1.31 per share against an estimate of $1.25

ILMN news

  • Press releasePRNewswire

    Illumina To Webcast Upcoming Investor Conference

  • Press releasePRNewswire

    Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

  • Press releasePRNewswire

    Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026

  • Press releasePRNewswire

    Illumina releases SpliceAI2 to help advance rare disease research

  • Piero Cingari

    10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

  • Press releasePRNewswire

    Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

  • Press releaseGlobe Newswire

    The Market Just Told You Which Layer Of AI Biology It Is Paying For

  • Press releasePRNewswire

    Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

Similar companies

Companies in the same industry as Illumina

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.